These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17574889)

  • 1. Concomitant, specific determination of growth hormone and pegvisomant in human serum.
    Ørskov H; Frystyk J; Nielsen C; Hansen AT; Weeke J; Jørgensen JO
    Growth Horm IGF Res; 2007 Oct; 17(5):431-4. PubMed ID: 17574889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant.
    Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F
    Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly.
    Madsen M; Fisker S; Feldt-Rasmussen U; Andreassen M; Kristensen LØ; Ørskov H; Jørgensen JO
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):92-100. PubMed ID: 23650996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay.
    Dias ML; Vieira JG; Abucham J
    Growth Horm IGF Res; 2013; 23(1-2):13-8. PubMed ID: 23206731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
    Manolopoulou J; Alami Y; Petersenn S; Schopohl J; Wu Z; Strasburger CJ; Bidlingmaier M
    Clin Chem; 2012 Oct; 58(10):1446-56. PubMed ID: 22908135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of pegvisomant on serum ghrelin and leptin levels in acromegalic patients.
    Roemmler J; Otto B; Arafat AM; Bidlingmaier M; Schopohl J
    Eur J Endocrinol; 2010 Nov; 163(5):727-34. PubMed ID: 20699383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.
    Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegvisomant interference in GH assays results in underestimation of GH levels.
    Paisley AN; Hayden K; Ellis A; Anderson J; Wieringa G; Trainer PJ
    Eur J Endocrinol; 2007 Mar; 156(3):315-9. PubMed ID: 17322491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
    J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
    Parkinson C; Burman P; Messig M; Trainer PJ
    J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.
    Paisley AN; Trainer PJ
    Horm Res; 2004; 62 Suppl 1():83-8. PubMed ID: 15761238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels.
    Droste M; Domberg J; Buchfelder M; Mann K; Schwanke A; Stalla G; Strasburger CJ
    Eur J Endocrinol; 2014 Jul; 171(1):59-68. PubMed ID: 24913198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.